Impact of Symprove in Ehlers-Danlos Syndrome
Research type
Research Study
Full title
A single-arm, decentralised, real-world evidence pilot study to assess the impact of Symprove in people with Ehlers-Danlos Syndrome (EDS)
IRAS ID
364450
Contact name
Asma Fikree
Contact email
Sponsor organisation
Symprove Ltd
Duration of Study in the UK
0 years, 8 months, 1 days
Research summary
The Ehlers-Danlos syndromes (EDS) are a group of 13 heritable connective tissue disorders that affect around 6000 people in the UK. Quality of life in people with EDS can be reduced due to chronic fatigue, joint dislocations and gastrointestinal symptoms. Management of gut symptoms in clinical practice is challenging and generally targeted to a specific symptom. Gut microbiome-targeted therapies, such as probiotics, have gained attention for their potential role on the gut microbiome. Gut supplements may be considered a novel strategy for supporting symptom management in people with EDS and warrants further exploration.
The aim of our pilot study is to assess the impact of a gut supplement called Symprove on EDS symptoms. Symprove is a water-based solution that contains billions of live and active bacteria, which can help
stimulate the good bacteria already in the gut. We will recruit a minimum of 150 participants with EDS. All participants will be recruited through Ehlers-Danlos Support UK.This is a non-randomised virtual study, which does not involve any study visits. After providing consent to take part using an online consent form, all participants will receive a 12-week course of Symprove to take once a day.
Participants will also receive a link to complete an online study survey about their symptoms at the beginning of the study before starting Symprove (Baseline), and at weeks 6 and 12 (follow-up). To assess the impact of Symprove we will compare the follow-up data to Baseline.The study is sponsored and organised by Symprove Ltd.
REC name
North West - Preston Research Ethics Committee
REC reference
26/NW/0017
Date of REC Opinion
4 Feb 2026
REC opinion
Further Information Favourable Opinion